MCL Literature Feed

This study shows ROR1 is heterogeneously expressed in 44% of MCL tumors, indicating that patient selection will be critical for developing ROR1-targeted therapies like ADCs or CAR-T.

This case of classical MCL rapidly transforming to a blastoid variant with CNS involvement highlights the poor prognosis and failure of BTKi and chemotherapy in this aggressive setting.

A novel 7-gene signature linked to ferroptosis predicts overall survival in MCL, identifying high-risk patients and suggesting potential new therapeutic targets like the MEK inhibitor Trametinib.

In a real-world cohort including MCL, the Hematotox-Score predicted early cytopenias post-CAR-T but not survival, underscoring the need for improved prognostic tools for toxicity management.

This case report details an extremely rare MCL presentation of bilateral hemorrhagic hypopyon, successfully treated with intravitreal rituximab, systemic chemotherapy, and radiation, expanding the differential for unusual ocular findings.

This phase 1 study established the safety and preliminary efficacy of a novel bortezomib, cladribine, and rituximab regimen for older, newly diagnosed mantle cell lymphoma patients.